Yoichi Kamei
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.
Journal: Journal of medical economics
Published: September 08, 2026
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Journal: Japanese journal of clinical oncology
Published: November 20, 2023
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.
Journal: Liver cancer
Published: September 15, 2020
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
Journal: BMC cancer
Published: October 11, 2017
Morphology of the fibular insertion of the posterolateral corner and biceps femoris tendon.
Journal: Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA
Published: February 22, 2016
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Journal: Japanese journal of clinical oncology
Published: December 05, 2014
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Journal: Cancer science
Published: August 07, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026